TPCs are an effective management strategy for symptomatic, recurrent, malignant pleural effusions. Their use as a first-line treatment is feasible and TPCs are particularly preferred for patients with trapped lung or those who are not considered good candidates for chemical pleurodesis because of short life-expectancy. There currently lacks sufficient evidence to recommend the use of TPCs in nonmalignant pleural diseases.